利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.017 秒)

    Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots
    1.
    发明申请
    Methods, Devices, And Compositions For Lysis Of Occlusive Blood Clots While Sparing Wound Sealing Clots 审中-公开
    方法，装置和组合物用于闭塞性血栓的裂解，同时保持伤口密封

    公开(公告)号：US20090226410A1

    公开(公告)日：2009-09-10

    申请号：US12165082

    申请日：2008-06-30

    申请人： Victor Gurewich ,  Jian-Ning Liu ,  Paolo Sarmientos

    发明人： Victor Gurewich ,  Jian-Ning Liu ,  Paolo Sarmientos

    IPC分类号： A61K38/45 ,  A61P9/00

    CPC分类号： A61L29/16 ,  A61K38/00 ,  A61L31/16 ,  A61L33/0047 ,  A61L2300/254 ,  C12N9/6462 ,  C12Y304/21073

    摘要： It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal wounds, e.g., after surgery or other tissue injury). Thus, these pro-UK mutants are excellent and safe thrombolytic agents. These advantages allow them to be used in a variety of new methods, devices, and compositions useful for thrombolysis and treating various cardiovascular disorders in clinical situations where administration of other known thrombolytic agents has been too risky or even contraindicated.

    摘要翻译： 现在已经发现，某些突变形式的前尿激酶（“pro-UK”），例如所谓的pro-UK突变体“M5”（Lys.sup.300.fwdarw.His））以这种方式 亲英国在裂解“不良”血块（堵塞血管的血块），同时将所谓“良好”血块中的止血纤维蛋白（例如手术或其他组织损伤后的血栓密封） 。 因此，这些pro-UK突变体是优秀和安全的溶栓剂。 这些优点使得它们可用于在临床情况下可用于溶栓和治疗各种心血管疾病的各种新方法，装置和组合物中，其中施用其它已知溶栓剂的风险太高或甚至禁忌。

    Treating atherosclerosis
    4.
    发明授权
    Treating atherosclerosis 有权
    治疗动脉粥样硬化

    公开(公告)号：US08507646B2

    公开(公告)日：2013-08-13

    申请号：US12528300

    申请日：2007-02-23

    申请人： Jian-Ning Liu

    发明人： Jian-Ning Liu

    IPC分类号： A61K38/00 ,  C07K14/00

    CPC分类号： C12N9/6462 ,  A61K38/00 ,  C12Y304/21073

    摘要： The present application features methods and compositions for treating patients suffering from atherosclerosis or at risk for developing atherosclerosis. The treatment includes administering to the patient a pharmaceutical composition that includes an agent capable of blocking the interaction between uPA and its receptor uPAR, e.g., an ATF or a fragment thereof, an anti-uPA antibody, a uPAR or a fragment thereof, or an antibody that specifically binds to uPAR.

    摘要翻译： 本申请的特征在于用于治疗患有动脉粥样硬化或有发展动脉粥样硬化风险的患者的方法和组合物。 治疗包括向患者施用药物组合物，其包含能够阻断uPA与其受体uPAR（例如ATF或其片段，抗uPA抗体，uPAR或其片段）或其受体uPAR之间的相互作用的试剂，或 特异性结合uPAR的抗体。

    PLASMA ANTI-DIABETIC NUCB2 PEPTIDE (PLADIN) AND USES THEREOF
    5.
    发明申请
    PLASMA ANTI-DIABETIC NUCB2 PEPTIDE (PLADIN) AND USES THEREOF 有权
    等离子体抗糖尿病NUCB2肽（PLADIN）及其用途

    公开(公告)号：US20100235935A1

    公开(公告)日：2010-09-16

    申请号：US12722575

    申请日：2010-03-12

    申请人： Jian-ning LIU

    发明人： Jian-ning LIU

    IPC分类号： A01K67/00 ,  A61K38/28 ,  A61K38/16 ,  A61K38/17 ,  A61K31/195 ,  C07K14/435 ,  C12Q1/02 ,  A61P3/06 ,  A61P3/10

    CPC分类号： A61K38/1709 ,  A01K2267/0362 ,  A61K38/57 ,  G01N33/5088 ,  G01N2800/042

    摘要： The present invention provides pladin (plasma anti-diabetic nucb2 peptide) polypeptide and functional equivalent thereof that are useful for treating diabetes. The present invention provides a method of treating diabetes by administering to a subject nesfatin-1, pladin, or a functional equivalent thereof. The present invention also provides a method of treating diabetes by administering to subject plasmin inhibitors.

    摘要翻译： 本发明提供可用于治疗糖尿病的pladin（血浆抗糖尿病nucb2肽）多肽及其功能等同物。 本发明提供了通过给予受试者nesfatin-1，pladin或其功能等同物来治疗糖尿病的方法。 本发明还提供了通过施用受试者的纤溶酶抑制剂来治疗糖尿病的方法。

    TREATING ATHEROSCLEROSIS
    6.
    发明申请
    TREATING ATHEROSCLEROSIS 有权
    治疗甲状腺功能亢进

    公开(公告)号：US20100143335A1

    公开(公告)日：2010-06-10

    申请号：US12528300

    申请日：2007-02-23

    申请人： Jian-ning Liu

    发明人： Jian-ning Liu

    IPC分类号： A61K39/395 ,  C07K14/00 ,  C07K7/08 ,  A61K38/16 ,  A61K38/10 ,  A61K38/08 ,  C07K16/00 ,  A61P9/10

    CPC分类号： C12N9/6462 ,  A61K38/00 ,  C12Y304/21073

    摘要： The present application features methods and compositions for treating patients suffering from atherosclerosis or at risk for developing atherosclerosis. The treatment includes administering to the patient a pharmaceutical composition that includes an agent capable of blocking the interaction between uPA and its receptor uPAR, e.g., an ATF or a fragment thereof, an anti-uPA antibody, a uPAR or a fragment thereof, or an antibody that specifically binds to uPAR.

    摘要翻译： 本申请的特征在于用于治疗患有动脉粥样硬化或有发展动脉粥样硬化风险的患者的方法和组合物。 治疗包括向患者施用药物组合物，其包含能够阻断uPA与其受体uPAR（例如ATF或其片段，抗uPA抗体，uPAR或其片段）或其受体uPAR之间的相互作用的试剂，或 特异性结合uPAR的抗体。

    Pro-urokinase mutants
    8.
    发明授权
    Pro-urokinase mutants 失效
    尿激酶突变体

    公开(公告)号：US5472692A

    公开(公告)日：1995-12-05

    申请号：US087163

    申请日：1993-07-02

    申请人： Jian-Ning Liu ,  Victor Gurewich

    发明人： Jian-Ning Liu ,  Victor Gurewich

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/46 ,  A61P7/02 ,  C07K14/745 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/72 ,  C12N15/57 ,  C12R1/91 ,  A61K38/49 ,  C12N9/48

    CPC分类号： C12Y304/21073 ,  C12N9/6459 ,  C12N9/6462 ,  C12Y304/21069 ,  A61K38/00

    摘要： The invention relates to thrombolytically active pro-urokinase (pro-UK) mutants comprising the amino acid sequence of native pro-UK, but including a mutation which causes the pro-UK mutants to induce less fibrinogenolysis and non-specific plasminogen activation than native pro-UK, to have at least a 10-fold lower intrinsic activity than native pro-UK, and to have substantially the same fibrin promotion and thrombolytic activity after plasmin activation compared to native pro-UK when administered to a patient.

    摘要翻译： 本发明涉及包含天然亲UK的氨基酸序列的溶栓活性的原尿激酶（pro-UK）突变体，但是包括引起前UK突变体诱导的纤维蛋白原分解和非特异性纤溶酶原激活的突变比天然pro -UK与天然亲UK相比具有至少10倍的内在活性，并且当给予患者时，与原始亲UK相比，在纤溶酶活化后具有基本上相同的纤维蛋白促进和血栓溶解活性。

    Use of Nestafin-1 in the Treatment for Diabetes
    9.
    发明申请
    Use of Nestafin-1 in the Treatment for Diabetes 审中-公开
    使用Nestafin-1治疗糖尿病

    公开(公告)号：US20100234274A1

    公开(公告)日：2010-09-16

    申请号：US12402848

    申请日：2009-03-12

    申请人： Jian-ning Liu

    发明人： Jian-ning Liu

    IPC分类号： A61K38/28 ,  A61K38/16 ,  A01K67/027 ,  G01N33/68

    CPC分类号： A61K38/1709 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0362 ,  G01N33/5058 ,  G01N33/5088

    摘要： The present invention provides a method of treating diabetes by increasing peripheral nesfatin-1. Peripheral nesfatin-1 can be increased by administration of nesfatin-1, conjugated nesfatin-1 that would not penetrate the blood-brain barrier, or plasmin inhibitors. The present invention also provides a method of screening for an agent that would increase peripheral or brain nesfatin-1.

    摘要翻译： 本发明提供了通过增加外周肾素素1治疗糖尿病的方法。 可以通过施用不渗透血脑屏障的nesfatin-1，缀合的nesfatin-1或纤溶酶抑制剂来增加外周nesfatin-1。 本发明还提供了筛选能增加外周或脑内皮素-1的药物的方法。